NCT05950139

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

Pilot Study of a Prophylactic Cancer Peptide Vaccine in Advanced ALK+ NSCLC

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety of a cancer peptide vaccine to prevent or delay acquired resistance in advanced ALK+ lung cancer patients currently on ALK targeted therapy.

Conditions

• NSCLC Stage IV
• ALK Fusion Protein Expression

Interventions

Type	Name	Description
BIOLOGICAL	Peptide vaccine	Peptide vaccine

Timeline

• Start date: 2024-05-13
• Primary completion: 2026-07-01
• Completion: 2029-07-01
• First posted: 2023-07-18
• Last updated: 2025-09-23

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study